Drug Profile
Research programme: pluripotent stem cell therapies - VistaGen
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator VistaGen Therapeutics
- Developer Duke University; VistaGen Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Heart failure; Metabolic disorders
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)
- 28 Aug 2019 No recent reports of development identified for research development in Heart-failure in USA (Parenteral)
- 28 Aug 2019 No recent reports of development identified for research development in Metabolic-disorders in USA (Parenteral)